CGRP is a potent vasodilator and nociceptive neuropeptide linked to migraine. CGRP receptors are heterodimers of receptor activity modifying protein 1 (RAMP1) and either calcitonin receptor-like receptor (CLR; forms canonical CGRP receptor) or calcitonin receptor (CT receptor; forms AMY 1 receptor). The goal of this study was to test whether transgenic mice globally expressing human RAMP1 have increased CGRP receptor activity and whether the receptors are sensitive to human selective antagonist telcagepant.
Introduction
Migraine is a prevalent and debilitating neurological condition that affects 11-18% of people worldwide Stovner et al., 2007; Stovner and Andree, 2010) . It has been ranked the sixth most disabling condition globally (Leonardi and Raggi, 2013; Global Burden of Disease Study, 2015) . Despite its high prevalence and societal impact, treatment options for migraine remain limited. The limitation is in part attributed to the various challenges faced with drug development stemming from the lack of understanding of the mechanisms responsible for migraine. This deficit can potentially be addressed by development of new animal models to complement and enhance available tests.
Over the years it has been established that the neuropeptide CGRP plays a key role in the pathogenesis of migraine (Villalon and Olesen, 2009; Ho et al., 2010; Russo, 2015) . In particular, clinical trials have demonstrated that small molecule CGRP receptor antagonists can abort acute migraine attacks. Olcegepant, the first antagonist evaluated in the clinic, was shown to be as efficacious as triptans, with limited side effects, but further development was stopped because of the inability to deliver the drug orally (Olesen et al., 2004; Doods et al., 2007) . Telcagepant is an oral CGRP receptor antagonist that has similar clinical efficacy (Ho et al., 2008b; Hewitt et al., 2011; Bigal et al., 2013) , but was discontinued after the discovery of potential liver toxicity associated with repeated use in a prophylactic study (Ho et al., 2014) . Other antagonists and monoclonal antibodies are currently undergoing development, but have not yet reached the public. In particular, clinical trials with CGRP monoclonal antibodies indicate that blocking CGRP or its receptor may also be an effective preventive strategy (Bigal et al., 2015) . While challenges remain, these trials support the need for good animal models for future testing of CGRP actions and CGRP-targeted therapeutics.
There are a number of migraine animal models currently available that have helped advance the field (Jansen- Olesen et al., 2013) . To complement these models, we reasoned that a more human-like model might facilitate the transition of CGRP-based drug development to clinical testing. An example is the nestin/human receptor activity modifying protein 1 (RAMP1) double transgenic mouse. These mice were sensitized to CGRP in the nervous system via over-expression of hRAMP1, the rate-limiting subunit of the CGRP receptor . The rationale for this mouse was based on clinical reports that injection of CGRP can cause migraine in migraineurs, but not in individuals without a history of migraines (Lassen et al., 2002) . This suggests that migraineurs are somehow sensitized to CGRP, which we proposed might be caused, or mimicked, by overexpression of the CGRP receptor . Based on enhanced light aversive behaviour and cutaneous allodynia (Marquez de Prado et al., 2009) , the nestin/hRAMP1 mice appear to provide a good model of some, but not necessarily all, migraine symptoms Russo, 2015) .
The model described in this study is similar to the nestin/hRAMP1 mice except that instead of hRAMP1 expression being restricted to the nervous system, hRAMP1 is expressed in all tissues. The strategy was to breed the same parental hRAMP1 line used to generate nestin/hRAMP1 mice with a mouse that expressed cre recombinase in germline cells. This early expression of cre recombinase permanently excised the upstream stop sequences from the hRAMP1 transgene in subsequent progeny, so that they no longer required cre recombinase to allow hRAMP1 expression. To do this, we used the EIIA-cre mice, which we had previously used to achieve ubiquitous overexpression of hRAMP1 in EIIa/hRAMP1 double transgenic mice (Sabharwal et al., 2010) . An advantage of the germline-excised lineage is that EIIa-cre can have mosaic expression (Lakso et al., 1996) , which we observed with the EIIa/hRAMP1 mice (Sabharwal et al., 2010) . Furthermore, while the cardiovascular phenotype of the EIIa/hRAMP1 mice has been reported (Chrissobolis et al., 2010; Sabharwal et al., 2010) , we had not previously tested whether CGRP receptor activity was increased nor whether the receptors were sensitive to human-receptor selective receptor antagonists. While the peptide fragment, CGRP-(8-37), is an antagonist that is equally potent at human and rodent CGRP receptors, the antagonists olcegepant and telcagepant are much more potent at human receptors (Taylor et al., 2006; Hopkins, 2011) .
To confirm that the RAMP1 component of rodent CGRP receptors is responsible for the decrease in potency of telcagepant in mice and to support the hypothesis that a rodent expressing hRAMP1 could recapitulate human pharmacology, stable cell lines were generated with various combinations of human or mouse RAMP1 (mRAMP1) and the G-protein coupled core receptor subunit calcitonin receptor-like receptor (CLR) or calcitonin receptor (CT receptor). While the CLR/RAMP1 complex has been viewed as the canonical CGRP receptor, recent studies have documented that CGRP activity at CT receptor/RAMP1 is nearly equivalent to CLR/RAMP1 (Walker et al., 2015; Walker et al., 2017) . CT receptor/RAMP1 has been designated as the amylin-1 (AMY 1 ) receptor since it is responsive to both CGRP and the related amylin peptide (Hay et al., 2005; Walker and Hay, 2013) . In the trigeminovascular system, both CGRP and AMY 1 receptors have been identified (Eftekhari et al., 2010; Eftekhari and Edvinsson, 2011; Walker et al., 2015; Bower et al., 2016) . The potency of CGRP receptor antagonists, with and without species differences, to block functional activity and binding was determined in cell cultures from both transgenic mice and clonal lines with both CLR/RAMP1 and CT receptor/RAMP1 proteins. by loxP sites followed by the hRAMP1 cDNA have been described previously (Zhang et al., 2007) . Hemizygous GFP-hRAMP1 mice (strain 28 412/3) were crossed with mice expressing cre recombinase under the control of the ubiquitous adenovirus EIIa promoter (B6.FVB-Tg(EIIa-cre) C5379Lmgd/J, Stock No. 003724, Jackson Laboratory) to produce double transgenic EIIa/hRAMP1 mice. The resultant double transgenic mice were then bred with non-transgenic littermates to generate progeny with the hRAMP1 transgene, but without cre recombinase. PCR genotyping using primers detecting hRAMP1 and cre was performed as described previously (Zhang et al., 2007) . Mice were housed under standard conditions at the University of Iowa with food and water ad libitum.
hRAMP1 gene expression was measured by real-time quantitative PCR (Q-PCR), using primer sequences and protocols previously described and validated by our team (Sabharwal et al., 2010) . The mRNA levels of both hRAMP1 and endogenous mouse (m)RAMP1 was determined using Power SYBR Green PCR Master Mix (Applied Biosystems, UK). Reactions were performed in triplicate using ABI SDS 7900 HT thermocycler. Analysis was performed using ABI SDS v2.4 software. The mRAMP1 and hRAMP1 Cq values were converted to absolute copy numbers and normalized to 50 000 copies of β-actin using standard curves generated with 1:10 serial dilutions of pGEM-QmRAMP1, pbsCX1-LEL-hRAMP1 and pGEM-Qmbeta-actin plasmids in 10 ng·mL À1 yeast tRNA. Total RAMP1 copies were summed and results reported as the mean-fold increase relative to control ± SEM from three pairs of control and hRAMP1 mice.
Primary cultures
Trigeminal ganglia (TG) were cultured from adult male and female mice (10-30 weeks old) that had been killed by CO 2 vapour, as recommended by University of Iowa guidelines. Ganglia were removed (generally in the morning), suspended in 10 mL ice-cold plating medium (25 mM HEPES, pH 7. To prepare membranes for binding assays, cells were harvested by centrifuging and washed once with PBS. Cell pellets were resuspended in 20 mM Tris, pH 7.4 with complete protease inhibitors (Roche Diagnostic, Indianapolis, IN, USA), then homogenized in a dounce homogenizer with 15 strokes on ice. Homogenate was spun (900× g) for 20 min at 4°C, supernatant collected and spun (1500× g) for an additional 20 min at 4°C. The supernatant was collected and spun again at high speed (>30 000× g) for 1 h at 4°C. The pellet was resuspended in assay buffer as a P2 membrane. Membrane protein concentration was measured with the Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Grand Island, NY, USA). (Sigma) at 37°C for 15 min. The agents were added to cells for 10 min at 37°C. Reactions were stopped by removing the medium followed by addition of 80 μL 0.1 M HCl. Plates were shaken lightly for 20 min at room temperature, cells were collected and centrifuged at 1000× g for 10 min. Supernatants were assayed directly following a dilution of at least 1:2 with EIA buffer (Cayman). Samples were stored at À80°C if not tested immediately. Each experimental condition was assayed in duplicate. Additional cAMP assays were performed in primary cultured neurons as previously described (Walker et al., 2014) . cAMP content was determined using the LANCE ultra cAMP detection kit (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA). 
Equilibrium and competition binding assays

Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . For cAMP assays from primary cultures, cAMP data were fitted to a sigmoidal dose-response curve to obtain maximal response (R max ), EC 50 and IC 50 values using a nonlinear regression curve-fitting program within PRISM GraphPad version 6. All values were reported as the mean ± SEM. The mean cAMP levels were compared by ANOVA and Tukey's test. Significance was accepted at P < 0.05. Statistical analyses were carried out using PRISM software.
For cAMP assays utilizing stable cell lines, compound EC 50 or IC 50 values were calculated by fitting the inhibition curves using nonlinear regression curve fit with variable slope (four parameters) in GraphPad Prism 6. Binding constant (K b ) values were determined using the following equation: K b = IC 50 /(1 + A/EC 50 ), where A is the concentration of the CGRP used in the cAMP assay and EC 50 is from the CGRP concentration-response curve for each cell line (Table 3) .
For all experiments, the health status of the cell culture was determined by light microscopy. The cultures were then randomized by arbitrary labelling of the dishes for various treatments. While the experimenter was blinded to the health status of the cells, because the dishes were labelled, the experimenter was not blinded for drug administration or subsequent data analysis. For all experiments, whenever possible, groups of similar size of n = 4-6 were used. However, in some cases, cultures were excluded for technical reasons (e.g. contamination, unhealthy cells and poor cell dispersion). For primary cultures, data were collected from multiple independent experiments, and because some treatments were included with every experiment as internal controls (e.g. vehicle and CGRP alone), for some studies, those groups have larger n values.
Figure 1
Expression pattern of hRAMP1 in global hRAMP1 mice. (A) Strategy for generating the global hRAMP1 mice containing the activated hRAMP1 allele in the germline. (B) Q-PCR measurement of RAMP1 levels in global hRAMP1 mice (hR) and control littermates. The levels of hRAMP1, mRAMP1 and β-actin were determined by real-time PCR. The copies of RAMP1 RNAs were calculated from standard curves and normalized to 50 000 copies of β-actin mRNA. Tissues are as follows: brain, spinal cord (SC), trigeminal ganglion (TG), liver, kidney, spleen, lungs, heart and aorta. (C) The fold increase of total RAMP1 (combined mouse and human) in global hRAMP1 mice tissues relative to mRAMP1 levels is indicated. Data are the mean ± SEM from five mice of each genotype.
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olcegepant (Lilly synthesized), human CGRP-(8-37) (Bachem), mouse CGRP-(8-37) (Bachem), human amylin (Bachem, Torrance, CA, USA), mouse amylin (Phoenix, Burlingame, CA, USA) and AC187 (Tocris, Bristol, UK).
Results
Transgenic hRAMP1 expression across tissues in global hRAMP1 mice
The global hRAMP1 line was generated by crossing CX1-GFPhRAMP1 mice with EIIa-cre mice ( Figure 1A) . Expression of hRAMP1 requires Cre to excise a floxed GFP upstream stop cassette (Sabharwal et al., 2010) . This results in expression of hRAMP1 in all tissues of the double transgenic EIIa/hRAMP1 mice, including primordial germ cells. As predicted, when the EIIa/hRAMP1 mice were crossed with non-transgenic littermates, the subsequent F1 progeny displayed germline transmission of the Cre-activated CX1-hRAMP1 transgene in approximately 50% of the progeny.
Global expression of hRAMP1 was confirmed in all tissues examined in the transgenic mice ( Figure 1B ). Expression in all tissues was predicted since the CX1 promoter was shown to ubiquitously drive GFP expression in the parental transgene line and hRAMP1 expression in the EIIA-cre-activated line in our previous studies (Chrissobolis et al., 2010; Sabharwal et al., 2010) . The combined levels of hRAMP1 and mRAMP1 RNAs were about 10-to 300-fold greater than endogenous mRAMP1 levels in transgenic and control littermates in a range of tissues ( Figure 1C ). This is overall greater expression than in the parental EIIa/hRAMP1 double transgenic mice (Sabharwal et al., 2010) . There were no significant differences between the levels of mRAMP1 RNA in tissues from transgenic mice versus control littermates.
Enhanced CGRP receptor activity in cultured vascular smooth muscle and trigeminal ganglia
In VSMC isolated from the aorta of global hRAMP1 mice, there was greatly enhanced CGRP receptor activity (Figure 2A) . There was almost a 10-fold increase in the Rmax compared with cells from littermate control mice (Figure 2 B) . Cultures from both transgenic and control non-transgenic mice had similar receptor efficacies. Global hRAMP1 cultures had an EC 50 of 2.0 × 10 À9 M and nontransgenic cultured cells had an EC 50 of 2.4 × 10 À9 M (Figure 2A, B) . These values fall within the published range of the CGRP receptor (Poyner et al., 2002) . In TG neurons, hRAMP1 overexpression also increased CGRP receptor signalling. However, unlike in the muscle cultures, in trigeminal cultures from control littermates, there was very little CGRP receptor activity detected at the EC 50 value predicted from other cell types ( Figure 2C ). This weak activity was greatly enhanced in trigeminal cultures from the global hRAMP1 mice ( Figure 2D for both global hRAMP1 and control mice, the activity is predicted to be greater at presumed physiological levels of CGRP. Thus, at CGRP concentrations near the EC 50 values, there was about a threefold increase in receptor activity in the global hRAMP1 cultures.
Telcagepant inhibition of CGRP receptor activity in global hRAMP1 mice
Cotreatment of telcagepant with CGRP significantly decreased the CGRP induction of cAMP in hRAMP1 muscle and trigeminal cultures, but not in the non-transgenic control cultures (Figure 3 ). In the muscle cultures, CGRP-(8-37) reduced the induction by CGRP in both hRAMP1 and control cultures ( Figure 3A) . Similarly, CGRP-(8-37) reduced the induction by CGRP in the hRAMP1 TG cultures ( Figure 3C ). However, CGRP-(8-37) had little or no effect on the control cultures, which is in agreement with the poor EC 50 values obtained in those cultures. A best fit IC 50 of 1.6 × 10 À7 M was established for telcagepant in cultures from hRAMP1 vascular smooth muscle ( Figure 3B ) and 1.2 × 10 À7 M from hRAMP1 TG ( Figure 3D ). Table 2 ). The concentrations of human and mouse CGRP utilized for the cyclase assays were determined following generation of concentration-response curves for each set of parameters ( Figure 6 ). EC 50 and EC 90 values for CGRP were calculated, and the EC 90 was used for subsequent cAMP experiments (Table 3) . The results from the binding studies were essentially reproduced in these studies with no differences in potency observed for hCGRP-(8-37) and rCGRP-(8-37) across the different receptors, but large differences observed for olcegepant and telcagepant (960-and 9695-fold less potent, respectively). Once again, the combination of hRAMP1 with mCLR resulted in K b values that were very similar to values determined with the hCGRP receptor. Taken together, these studies suggest that replacement of mRAMP1 with hRAMP1 results in human-like pharmacological effects for two CGRP receptor antagonists well known to be species-selective. Functional characterization of CGRP antagonists on cells stably expressing hAMY 1 or mAMY 1 receptors was completed. Inhibition of cAMP production by olcegepant and telcagepant following activation by human or mouse amylin (Figure 7 ) or human CGRP (Figure 8 ) was measured.
K b values were calculated and compared ( Table 2 ). The concentrations of human amylin, mouse amylin and human CGRP utilized for the cyclase assays were determined following generation of concentration-response curves for each set of parameters (Figures 9 and 10) . EC 50 and EC 90 values for amylin and CGRP were calculated, and the EC 90 was used for subsequent cAMP experiments (Table 3) . The species differences in potency seen with the CGRP receptor a Mean ± SEM (n = 9 for hCGRP, mCGRP and mhCGRP receptor assays; n = 6-11 for hAMY 1 receptor assay; n = 24 for mAMY 1 receptor assay). b ND, not determined.
BJP K J Bohn et al.
were once again observed at the AMY 1 receptor. Olcegepant and telcagepant were at least 100 000× and 16 000× less potent respectively at the mAMY 1 versus the hAMY 1 receptor. The potency for these two molecules at the hAMY 1 receptor was similar, independent of agonist.
Discussion
In order to better facilitate drug development, it is necessary to have a more in-depth understanding of the currently available animal models of migraine. It was previously shown that RAMP1 is the rate-limiting subunit of the CGRP receptor and is predicted to be a key target in migraine . The aim of this study was to further characterize the CGRP receptor in a transgenic hRAMP1 mouse model. We chose an overexpression strategy for two reasons. First, based on human CGRP injection studies (Lassen et al., 2002) , we reasoned that people with migraine are more sensitive to CGRP, and hence, we wanted to generate a CGRP-sensitized mouse model. Second, we wanted an excess of human subunit to outcompete the mouse subunit, in order to have a pharmacologically relevant target for the screening of new treatments. While the specific mechanisms of migraine pathogenesis remain unknown, it is generally accepted that migraine involves the trigeminovascular system (Goadsby et al., 2002; Pietrobon and Striessnig, 2003; Messlinger, 2009) . Thus, we chose to look at TG neurons and VSMC. Both tissues have been reported to express endogenous CGRP receptors (Fabbretti et al., 2006; Zhang et al., 2006) . As predicted, global hRAMP1 mice are expressing human RAMP1 transcripts in all tissues tested as observed with the EIIA/hRAMP1 mice (Chrissobolis et al., 2010) . However, we did observe 10-to 50-fold greater overexpression in some tissues, such as kidney and heart than in EIIA/hRAMP1. Some a Mean ± SEM (n = 8 for hCGRP, mCGRP and mhCGRP receptor assays; n = 24 for hAMY 1 receptor assay; n = 16 for mAMY 1 receptor assay)
possible reasons for this difference may include the following: (i) EIIA/hRAMP1 mice had a mosaic expression pattern, including in the heart (Sabharwal et al., 2010) ; (ii) natural genetic or epigenetic modifications over the past 7 years; or (iii) improved efficiency in the mRAMP1 qPCR conditions, which may have previously overestimated the amount of mRAMP1 in tissues with low endogenous levels, such as heart and kidney. Whichever the reason, it is clear that the global hRAMP1 mice have higher expression of hRAMP1 than mRAMP1 RNA in all tissues tested. Unexpectedly, while hRAMP1 overexpression enhanced CGRP-induced signalling, the mechanism differed between vascular muscle and TG neurons. The predominant effect on vascular muscle was a 10-fold increase in the maximal cAMP response to CGRP, while the predominant effect on TG neurons was a 40-fold increase in CGRP potency (decreased EC 50 ). The effect of hRAMP1 on the maximal cAMP response in muscle cells is consistent with our finding that the maximal CGRP-induced vasodilatation of carotid and basilar arteries in vitro, as well as cerebral arterioles in vivo, was enhanced about twofold in EIIA/hRAMP1 mice (Chrissobolis et al., 2010) . The EIIA/hRAMP1 mice are the progenitors of the global mice of this study, and while not identical, they have a similar ubiquitous hRAMP1 expression pattern. Future studies measuring vascular tone in vivo should be interesting.
Likewise, the greater effect of hRAMP1 on CGRP potency in neurons is consistent with our previous report of enhanced CGRP signalling following overexpression of hRAMP1 in rat TG neurons by viral-mediated gene transfer (Zhang et al., 2007) . However, it should be noted in that study that the potency was increased by only sixfold and there was a 1.8- fold increase in Rmax. These quantitative differences may reflect differences between gene transfer and transgenic expression, neonatal rat versus adult mouse, or more glia in the rat than mouse cell cultures. Either way, the observed differences between tissues suggest that genetic or epigenetic modulation of RAMP1 levels in mouse models or patients may have tissue-specific effects on CGRP receptor activity. Whether or how these different effects translate to migraine susceptibility remains to be seen, but consideration of this issue may be important for targeted delivery of CGRP-based therapeutics.
How might modulating RAMP1 levels differentially affect the efficacy (Rmax) versus potency (EC 50 ) of CGRP receptor activity in different tissues? While speculative, it seems likely that potential differences in the endogenous levels of receptor subunits (CLR, CT receptor) and RAMPs (RAMPs 1, 2, 3) between muscle and neurons could dictate the effect of elevated RAMP1 on CGRP signalling. For example, in muscle, elevated RAMP1 could primarily increase trafficking of CLR from internal stores, which would increase the number of cell surface receptors, thereby increasing Rmax. On the other hand, in neurons, elevated RAMP1 could cause a shift from low-affinity receptors, such as CLR/RAMP2 or 3 or CT receptor alone or CT receptor/RAMP2 or 3, to the highaffinity CLR/RAMP1 and CT receptor/RAMP1 receptors, which would increase potency without much of an increase in receptors measured at high ligand concentrations. In addition, RAMP1-mediated differences in engagement of G proteins and/or recruitment of different G protein signalling pathways may also contribute to the differences between muscle and neurons.
Our results demonstrate that global hRAMP1 transgenic mice have a partially humanized CGRP receptor phenotype compared with the non-transgenic control. This was shown in two different tissues. In the tissues from hRAMP1 mice, telcagepant effectively blocked CGRP-induced cAMP production, but had no apparent effect on the non-transgenic control cultures. As a control, the non-species selective antagonist CGRP-(8-37) blocked cAMP accumulation in both hRAMP1 and control cultures. Telcagepant dose-response curves revealed almost identical IC 50 values of 1.6 × 10 À7 M for both muscle and neuronal cells. However, the IC 50 values from hRAMP1 tissues were about 10-100 times greater than IC 50 values reported in the literature for hCLR/RAMP1 (2-11 nM) (Ho et al., 2008a; Hopkins, 2011) . This discrepancy could indicate that the mice have only a partially humanized receptor phenotype despite the robust overexpression of hRAMP1 RNA. Alternatively, it could also indicate that the predominant CGRP receptor in these tissues may be the AMY 1 (CT receptor/RAMP1) receptor. While the majority of research and clinical development has focused on the CGRP receptor, both olcegepant and telcagepant can act as antagonists at the human AMY 1 receptor, albeit to lesser degrees (Hay et al., 2006a; Walker et al., 2015) . Consistent with these previous reports, in this study, we measured antagonism of the AMY 1 receptor at about 10-50-fold higher IC 50 values than at the classical CLR/RAMP1 CGRP receptor in programmed cell lines.
To better interpret the transgenic mouse data, cell lines that expressed human and mouse CGRP and AMY 1 receptors, as well as hybrid mouse/human receptors, were generated. This allowed us to assess differences in binding and functional potency for a set of four CGRP receptor antagonists, of which two were known to have large differences in potency across species. The combination of hRAMP1 with mCLR (m/hCGRP receptor) resulted in K i and K b values that were very similar to values determined with hCGRP receptor for olcegepant and telcagepant. These studies suggest that replacement of mRAMP1 with hRAMP1 results in human-like pharmacological effects for two CGRP receptor antagonists well known to be species-selective and predict that generation of a transgenic animal with mRAMP1 totally replaced by hRAMP1 would result in an animal with human-like potencies for CGRP receptor antagonists. The widely discrepant K b values from the functional cAMP assay on the mouse and human CGRP receptor (1415 and 0.146 nM, respectively) for telcagepant further support the premise that the potency measured in the muscle and neuronal cells (IC 50 = 160 nM) is suggestive of a partially humanized receptor phenotype. Alternatively, the data could support the possibility mentioned above that the predominant CGRP receptor on trigeminal nerves and vascular muscle in these mice might instead be the AMY 1 receptor.
Currently, CGRP receptor antagonism is promising for both abortive and preventive treatment of migraine. Recent clinical trials have opened the door for monoclonal CGRP antibodies, which may prove to be an effective prophylactic treatment option for migraine (Bigal et al., 2015) . Yet current migraine drug development remains limited, and one contributing factor to this limitation is the availability of appropriate animal models. With the widely accepted fact that CGRP plays a role in the pathogenesis of migraine, development of the global hRAMP1 mouse may facilitate the development of new drug targets. In addition, this mouse may also facilitate studies on the biological role of the AMY 1 receptor in the biology and migraine pathogenesis of CGRP and possibly amylin. Finally, because RAMP1 is associated with multiple receptors, such as the VIP/PACAP receptors (Hay et al., 2006b; Klein et al., 2016) , these mice may also be useful for testing non-CGRP-based therapies.
In conclusion, the global hRAMP1 mice may be useful for future development and screening of migraine therapeutic agents.
